Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $3.68 billion. The enterprise value is $3.60 billion.
Important Dates
The last earnings date was Tuesday, November 5, 2024, after market close.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 61.46 million shares outstanding. The number of shares has increased by 6.06% in one year.
| Current Share Class | 61.46M |
| Shares Outstanding | 61.46M |
| Shares Change (YoY) | +6.06% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 0.58% |
| Owned by Institutions (%) | 85.91% |
| Float | 45.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.86 |
| Forward PS | 20.20 |
| PB Ratio | n/a |
| P/TBV Ratio | 767.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 32.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.49, with a Debt / Equity ratio of 0.74.
| Current Ratio | 3.49 |
| Quick Ratio | 3.25 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.47 |
Financial Efficiency
Return on equity (ROE) is -147.90% and return on invested capital (ROIC) is -71.39%.
| Return on Equity (ROE) | -147.90% |
| Return on Assets (ROA) | -46.24% |
| Return on Capital (ROIC) | -71.39% |
| Revenue Per Employee | $497,920 |
| Profits Per Employee | -$1.16M |
| Employee Count | 226 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.18 |
Taxes
In the past 12 months, RYTM has paid $632,000 in taxes.
| Income Tax | 632,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +79.75% in the last 52 weeks. The beta is 2.09, so RYTM's price volatility has been higher than the market average.
| Beta (5Y) | 2.09 |
| 52-Week Price Change | +79.75% |
| 50-Day Moving Average | 53.16 |
| 200-Day Moving Average | 45.76 |
| Relative Strength Index (RSI) | 57.63 |
| Average Volume (20 Days) | 697,076 |
Short Selling Information
The latest short interest is 8.36 million, so 13.60% of the outstanding shares have been sold short.
| Short Interest | 8.36M |
| Short Previous Month | 8.46M |
| Short % of Shares Out | 13.60% |
| Short % of Float | 18.55% |
| Short Ratio (days to cover) | 27.30 |
Income Statement
In the last 12 months, RYTM had revenue of $112.53 million and -$261.57 million in losses. Loss per share was -$4.33.
| Revenue | 112.53M |
| Gross Profit | 99.72M |
| Operating Income | -265.51M |
| Pretax Income | -258.09M |
| Net Income | -261.57M |
| EBITDA | -263.92M |
| EBIT | -265.51M |
| Loss Per Share | -$4.33 |
Full Income StatementBalance Sheet
The company has $298.39 million in cash and $113.27 million in debt, giving a net cash position of $185.12 million or $3.01 per share.
| Cash & Cash Equivalents | 298.39M |
| Total Debt | 113.27M |
| Net Cash | 185.12M |
| Net Cash Per Share | $3.01 |
| Equity (Book Value) | 152.70M |
| Book Value Per Share | 0.18 |
| Working Capital | 242.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$124.42 million and capital expenditures $1,000, giving a free cash flow of -$124.42 million.
| Operating Cash Flow | -124.42M |
| Capital Expenditures | 1,000 |
| Free Cash Flow | -124.42M |
| FCF Per Share | -$2.02 |
Full Cash Flow StatementMargins
Gross margin is 88.61%, with operating and profit margins of -235.95% and -230.11%.
| Gross Margin | 88.61% |
| Operating Margin | -235.95% |
| Pretax Margin | -229.55% |
| Profit Margin | -230.11% |
| EBITDA Margin | -234.53% |
| EBIT Margin | -235.95% |
| FCF Margin | -126.20% |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.06% |
| Shareholder Yield | -6.06% |
| Earnings Yield | -7.06% |
| FCF Yield | -3.36% |
Dividend DetailsAnalyst Forecast
The average price target for RYTM is $62.30, which is 4.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $62.30 |
| Price Target Difference | 4.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 68.19% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 1.41 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.41 |
| Piotroski F-Score | 3 |